Citations (150)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (21)
Annemarie Voss, Bianca Kollhorst, Katharina Platzbecker, Ute Amann & Ulrike Haug. (2023) Risk Profiles of New Users of Oral Anticoagulants Between 2011 and 2019 in Germany. Clinical Epidemiology 15, pages 827-837.
Read now
Read now
Steven Deitelzweig, Manuela Di Fusco, Amiee Kang, Mirko Savone, Ruth Mokgokong, Allison Keshishian, Cynthia Gutierrez & Joseph C. Cappelleri. (2021) Real-world persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis. Current Medical Research and Opinion 37:6, pages 891-902.
Read now
Read now
Ameenathul M. Fawzy, Wang-Yang Yang & Gregory YH. Lip. (2019) Safety of direct oral anticoagulants in real–world clinical practice: translating the trials to everyday clinical management. Expert Opinion on Drug Safety 18:3, pages 187-209.
Read now
Read now
Jorge Romero, Ricardo Avendano, Juan Carlos Diaz, Jose Taveras, Florentino Lupercio & Luigi Di Biase. (2019) Is it safe to stop oral anticoagulation after catheter ablation for atrial fibrillation?. Expert Review of Cardiovascular Therapy 17:1, pages 31-41.
Read now
Read now
Jean-Baptiste Briere, Kevin Bowrin, Craig Coleman, Laurent Fauchier, Pierre Levy, Kerstin Folkerts, Mondher Toumi, Vanessa Taieb, Aurélie Millier & Olivia Wu. (2019) Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review. Expert Review of Pharmacoeconomics & Outcomes Research 19:1, pages 27-36.
Read now
Read now
Takanori Ikeda, Masahiro Yasaka, Makoto Kida & Miki Imura. (2018) A survey of reasons for continuing warfarin therapy in the era of direct oral anticoagulants in Japanese patients with atrial fibrillation: the SELECT study. Patient Preference and Adherence 12, pages 135-143.
Read now
Read now
Sabrina Mueller, Antje Groth, Stefan G Spitzer, Anja Schramm, Andreas Pfaff & Ulf Maywald. (2018) Real-world effectiveness and safety of oral anticoagulation strategies in atrial fibrillation: a cohort study based on a German claims dataset. Pragmatic and Observational Research 9, pages 1-10.
Read now
Read now
A. John Camm & Keith A. A. Fox. (2018) Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban. Current Medical Research and Opinion 34:11, pages 1945-1957.
Read now
Read now
Philip S. Wells, Anthonie W. A. Lensing, Lloyd Haskell, Bennett Levitan, François Laliberté, Michael Durkin, Veronica Ashton, Yongling Xiao, Concetta Crivera, Dominique Lejeune, Jeff Schein & Patrick Lefebvre. (2018) Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results. Journal of Medical Economics 21:6, pages 587-594.
Read now
Read now
S. Deitelzweig, C. Farmer, X. Luo, X. Li, L. Vo, J. Mardekian, K. Fahrbach & A. Ashaye. (2018) Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis. Current Medical Research and Opinion 34:3, pages 487-498.
Read now
Read now
Shun Kohsaka, Tatsunori Murata, Naoko Izumi, Jun Katada, Feng Wang & Yasuo Terayama. (2017) Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data. Current Medical Research and Opinion 33:11, pages 1955-1963.
Read now
Read now
Steven Deitelzweig, Xuemei Luo, Kiran Gupta, Jeffrey Trocio, Jack Mardekian, Tammy Curtice, Melissa Lingohr-Smith, Brandy Menges & Jay Lin. (2017) Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Current Medical Research and Opinion 33:10, pages 1745-1754.
Read now
Read now
S. Deitelzweig, C. Farmer, X. Luo, L. Vo, X. Li, M. Hamilton, R. Horblyuk & A. Ashaye. (2017) Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies. Current Medical Research and Opinion 33:9, pages 1583-1594.
Read now
Read now
Alpesh Amin, Allison Keshishian, Jeffrey Trocio, Oluwaseyi Dina, Hannah Le, Lisa Rosenblatt, Xianchen Liu, Jack Mardekian, Qisu Zhang, Onur Baser & Lien Vo. (2017) Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Current Medical Research and Opinion 33:9, pages 1595-1604.
Read now
Read now
Leon A. Simons, Michael Ortiz, Ben Freedman, Benjamin J. Waterhouse & David Colquhoun. (2017) Medium- to long-term persistence with non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience. Current Medical Research and Opinion 33:7, pages 1337-1341.
Read now
Read now
Aitor Lanas-Gimeno & Angel Lanas. (2017) Risk of gastrointestinal bleeding during anticoagulant treatment. Expert Opinion on Drug Safety 16:6, pages 673-685.
Read now
Read now
Erin R. Weeda, C. Michael White, W. Frank Peacock & Craig I. Coleman. (2016) Rates of major bleeding with rivaroxaban in real-world studies of nonvalvular atrial fibrillation patients: a meta-analysis. Current Medical Research and Opinion 32:6, pages 1117-1120.
Read now
Read now
Paolo Prandoni. (2015) Adherence to the novel oral anticoagulants: an unmet need. Current Medical Research and Opinion 31:12, pages 2175-2177.
Read now
Read now
Mikhail S Dzeshka & Gregory YH Lip. (2015) Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Expert Opinion on Pharmacotherapy 16:17, pages 2661-2678.
Read now
Read now
Gines Escolar, Xavier Carne & Eduardo Arellano-Rodrigo. (2015) Dosing of rivaroxaban by indication: getting the right dose for the patient. Expert Opinion on Drug Metabolism & Toxicology 11:10, pages 1665-1677.
Read now
Read now
Gonzalo Barón-Esquivias, Francisco Fernández-Avilés, Felipe Atienza, Pablo Pastor Pueyo, Rocío Toro & Marcelo Sanmartín Fernández. (2015) Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation. Expert Review of Cardiovascular Therapy 13:4, pages 341-353.
Read now
Read now
Articles from other publishers (129)
Ze Li, Siyu Yang, Zixin Hua, Yanxia Lu & Xingang Li. (2023) Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation. Naunyn-Schmiedeberg's Archives of Pharmacology.
Crossref
Crossref
Mark Alberts, Maryia Zhdanava, Dominic Pilon, Gabrielle Caron-Lapointe, Patrick Lefebvre, Brahim Bookhart & Akshay Kharat. (2023) Ischemic Stroke and Systemic Embolism Among One-and-Done Direct Oral Anticoagulant Users with Non-valvular Atrial Fibrillation. Advances in Therapy 40:5, pages 2339-2354.
Crossref
Crossref
Jeffrey S. Berger, Veronica Ashton, François Laliberté, Guillaume Germain, Brahim Bookhart, Dominique Lejeune, Julien Boudreau, Patrick Lefebvre & Matthew R. Weir. (2023) Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population. Advances in Therapy 40:3, pages 1224-1241.
Crossref
Crossref
Seung-Kee Min, Ji-Sun Kim, Jang Yong Kim, Ui Jun Park, Taehoon Lee, Jin Mo Kang, Sun Cheol Park, Won-Il Choi, Ki-Hyuk Park & Martin Gebel. (2022) Characteristics and Effect of Rivaroxaban on Venous Thromboembolism in Korean Patients Compared to Western Population: A Subgroup Analysis from XALIA(-LEA) Study. Vascular Specialist International 38.
Crossref
Crossref
Joshua Lambert, Harpal Sandhu, Emily Kean, Teenu Xavier, Aviv Brokman, Zachary Steckler, Lee Park & Arnold Stromberg. (2022) A strategy to identify event specific hospitalizations in large health claims databases. BMC Health Services Research 22:1.
Crossref
Crossref
Hind M. Alosaimi, Saeed Alqahtani, Bander Balkhi, Mishari Alqahtani, Faisal Alzamil, Abdulaziz Alhossan, Fatmah S. Alqahtany, Abdullah A. Alharbi, Nawaf Abdullah Alqahtani, Hanan Albackr, Ghada Elgohary & Farjah H. Algahtani. (2022) A retrospective study of real-world effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation and venous thromboembolism in Saudi Arabia. PeerJ 10, pages e13974.
Crossref
Crossref
Yinzhu Jin, Sebastian Schneeweiss, Dave Merola & Kueiyu Joshua Lin. (2022) Impact of longitudinal data-completeness of electronic health record data on risk score misclassification. Journal of the American Medical Informatics Association 29:7, pages 1225-1232.
Crossref
Crossref
O. V. Averkov & L. N. Mishchenko. (2021) Gastrointestinal Bleeding: a Cardiologist's Point of View. Rational Pharmacotherapy in Cardiology 17:5, pages 771-778.
Crossref
Crossref
Fuwei Liu, Yunyao Yang, Winglam Cheng, Jianyong Ma & Wengen Zhu. (2021) Reappraisal of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine 8.
Crossref
Crossref
Luise Tittl, Sandra Marten, Christiane Naue & Jan Beyer-Westendorf. (2021) 5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry. Thrombosis Research 202, pages 24-30.
Crossref
Crossref
Miney Paquette, Lawrence Mbuagbaw, Alfonso Iorio & Robby Nieuwlaat. (2021) Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation. European Heart Journal - Cardiovascular Pharmacotherapy 7:3, pages 251-260.
Crossref
Crossref
Wei-Jia Li, Paraschos Archontakis-Barakakis, Leonidas Palaiodimos, Dimitrios Kalaitzoglou, Lazaros Tzelves, Apostolos Manolopoulos, Yu-Chiang Wang, Stefanos Giannopoulos, Robert Faillace & Damianos G Kokkinidis. (2021) Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis. World Journal of Cardiology 13:4, pages 82-94.
Crossref
Crossref
Youfei Yu, Min Zhang, Xu Shi, Megan E. V. Caram, Roderick J. A. Little & Bhramar Mukherjee. (2021)
A comparison of parametric propensity
score‐based
methods for causal inference with multiple treatments and a binary outcome
. Statistics in Medicine 40:7, pages 1653-1677.
Crossref
Crossref
Valentina Lorenzoni, Salvatore Pirri & Giuseppe Turchetti. (2021) Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available “Real-World” Evidence: The Italian National Health System Perspective. Clinical Drug Investigation 41:3, pages 255-267.
Crossref
Crossref
M. Rosa Dalmau Llorca, Carina Aguilar Martín, Noèlia Carrasco-Querol, Zojaina Hernández Rojas, Emma Forcadell Drago, Dolores Rodríguez Cumplido, Josep M. Pepió Vilaubí, Elisabet Castro Blanco, Alessandra Q. Gonçalves & José Fernández-Sáez. (2021) Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study). International Journal of Environmental Research and Public Health 18:5, pages 2244.
Crossref
Crossref
Lena M. Paschke, Kerstin Klimke, Attila Altiner, Dominik von Stillfried & Maike Schulz. (2020) Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study. BMC Medicine 18:1.
Crossref
Crossref
M. Corrochano, B. Jiménez, J. Millón, I. Gich, M. Rambla, E. Gil, P. Caparrós, R. Macho & J. C. Souto. (2020) Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: clinical outcomes in a single centre cohort after long-term follow-up. BMC Cardiovascular Disorders 20:1.
Crossref
Crossref
Jacques Bouget, Frédéric Balusson, Maxime Maignan, Laure Pavageau, Pierre‐Marie Roy, Karine Lacut, Lucie‐Marie Scailteux, Emmanuel Nowak & Emmanuel Oger. (2020) Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3‐year period population‐based prospective cohort study. British Journal of Clinical Pharmacology 86:12, pages 2519-2529.
Crossref
Crossref
Magdalena Domek, Jakub Gumprecht, Wern Yew Ding, Gregory Y H Lip & Deirdre A Lane. (2020) Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials. European Heart Journal Supplements 22:Supplement_I, pages I1-I12.
Crossref
Crossref
Monika Kozieł, Michał Mazurek, Christine Teutsch, Hans-Christoph Diener, Sergio J. Dubner, Jonathan L. Halperin, Chang-Sheng Ma, Kenneth J. Rothman, Axel Brandes, Miney Paquette, Kristina Zint, Lionel Riou França, Shihai Lu, Dorothee B. Bartels, Menno V. Huisman & Gregory Y. H. Lip. (2020) Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up. Journal of Clinical Medicine 9:6, pages 1969.
Crossref
Crossref
Alba María Costa Grille, Irene Criado Martín & Roberto Petidier Torregrossa. 2020. Epidemiology and Treatment of Atrial Fibrillation. Epidemiology and Treatment of Atrial Fibrillation.
Zhi-Chun Gu, An-Hua Wei, Chi Zhang, Xin-Hua Wang, Le Zhang, Long Shen, Zheng Li, Mang-Mang Pan, Xiao-Yan Liu, Jun Pu & Hou-Wen Lin. (2020) Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 18:4, pages 792-799.e61.
Crossref
Crossref
Aya F. OzakiAustin S. ChoiQuan T. LeDennis T. KoJanet K. HanSandy S. ParkCynthia A. Jackevicius. (2020) Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes 13:3.
Crossref
Crossref
Kwang-No Lee, Jong-Il Choi, Ki Yung Boo, Do Young Kim, Yun Gi Kim, Suk-Kyu Oh, Yong-Soo Baek, Dae In Lee, Seung-Young Roh, Jaemin Shim, Jin Seok Kim & Young-Hoon Kim. (2020) Effectiveness and Safety of Off-label Dosing of Non–vitamin K Antagonist Anticoagulant for Atrial Fibrillation in Asian Patients. Scientific Reports 10:1.
Crossref
Crossref
Hyeongsoo Kim, Young Soo Lee, Tae-Hoon Kim, Myung-Jin Cha, Jung Myung Lee, Junbeom Park, Jin-Kyu Park, Ki-Woon Kang, Jaemin Shim, Jae-Sun Uhm, Hyung Wook Park, Eue-Keun Choi, Jin-Bae Kim, Changsoo Kim, Jun Kim & Boyoung Joung. (2020) A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF). The Korean Journal of Internal Medicine 35:1, pages 99-108.
Crossref
Crossref
Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira, Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous & Wanrudee Isaranuwatchai. (2020) Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration. BMJ Open 10:1, pages e032884.
Crossref
Crossref
Linda P T Joosten, Sander van Doorn, Arno W Hoes, Melchior C Nierman, Nynke M Wiersma, Huiberdina L Koek, Martin E W Hemels, Menno V Huisman, Kit C Roes, Rutger M van den Bor, Wim F Buding, Frans H Rutten & Geert-Jan Geersing. (2019) Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial. BMJ Open 9:12, pages e032488.
Crossref
Crossref
Ayako Ohshima, Toshihiro Koyama, Aiko Ogawa, Yoshito Zamami, Hiroyoshi Y Tanaka, Yoshihisa Kitamura, Toshiaki Sendo, Shiro Hinotsu, Michael W Miller & Mitsunobu R Kano. (2019) Oral anticoagulants usage in Japanese patients aged 18–74 years with non-valvular atrial fibrillation: a retrospective analysis based on insurance claims data. Family Practice 36:6, pages 685-692.
Crossref
Crossref
O. D. OstroumovaA. I. Kochetkov, S. P. Korchagina, T. M. OstroumovaM. S. Chernyaeva & A. A. Kirichenko. (2019) Anticoagulant Therapy as a Tool for the Prevention of Cognitive Impairment Associated with Atrial Fibrillation. Rational Pharmacotherapy in Cardiology 15:5, pages 713-724.
Crossref
Crossref
J.L. Llisterri Caro, S. Cinza-Sanjurjo, J. Polo Garcia & M.A. Prieto Díaz. (2019) Utilización de los anticoagulantes orales de acción directa en Atención Primaria de España. Posicionamiento de SEMERGEN ante la situación actual. Medicina de Familia. SEMERGEN 45:6, pages 413-429.
Crossref
Crossref
Jacques Bouget, Frédéric Balusson, Lucie‐Marie Scailteux, Maxime Maignan, Pierre‐Marie Roy, Erwan L'her, Laure Pavageau & Emmanuel Nowak. (2019)
Major bleeding with antithrombotic agents: a 2012–2015 study using the French nationwide Health Insurance database linked to emergency department records within five areas – rationale and design of
SACHA
study
. Fundamental & Clinical Pharmacology 33:4, pages 443-462.
Crossref
Crossref
Chandrasekar Gopalakrishnan, Sebastian Schneeweiss, Dorothee B. Bartels, Kristina Zint, Adrian Santiago Ortiz & Krista F. Huybrechts. (2019) Evaluating utilization patterns of oral anticoagulants in routine care. Journal of Thrombosis and Haemostasis 17:7, pages 1033-1043.
Crossref
Crossref
Keiko Hosohata, Saki Oyama, Iku Niinomi, Tomohito Wakabayashi, Ayaka Inada & Kazunori Iwanaga. (2019) Comparison of Safety Profiles of New Oral Anticoagulants with Warfarin Using the Japanese Spontaneous Reporting Database. Clinical Drug Investigation 39:7, pages 665-670.
Crossref
Crossref
Yuliya P. Skirdenko, Nikolay A. Nikolaev, Maria А. Livzan & Anton V. Ershov. (2019) Anticoagulant Therapy for Atrial Fibrillation in Real Practice: Problems and Prospects. Annals of the Russian academy of medical sciences 74:2, pages 98-107.
Crossref
Crossref
Zhe Sun, Yuqi Liu, Ye Zhang, Xinhong Guo & Yong Xu. (2019) Differences in safety and efficacy of oral anticoagulants in patients with non‐valvular atrial fibrillation: A Bayesian analysis. International Journal of Clinical Practice 73:4, pages e13308.
Crossref
Crossref
Carlos Escobar, Julio Martí-Almor, Alejandro Pérez Cabeza & M. José Martínez-Zapata. (2019) Anticoagulantes orales directos frente a antagonistas de la vitamina K en pacientes con fibrilación auricular de la práctica clínica: revisión sistemática y metanálisis. Revista Española de Cardiología 72:4, pages 305-316.
Crossref
Crossref
Carlos Escobar, Julio Martí-Almor, Alejandro Pérez Cabeza & M. José Martínez-Zapata. (2019) Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis. Revista Española de Cardiología (English Edition) 72:4, pages 305-316.
Crossref
Crossref
Yu. P. Skirdenko & N. A. Nikolaev. (2019) Contribution of anticoagulant therapy adherence to the risk of complications of atrial fibrillation. Russian Journal of Cardiology:2, pages 64-69.
Crossref
Crossref
O. I. Efimova & T. V. Pavlova. (2019) CHOICE OF DIRECT ORAL ANTICOAGULANTS BASED ON THE INDIVIDUAL APPROACH. Translational Medicine 5:6, pages 10-22.
Crossref
Crossref
N. N. Kryukov, E. V. Sayutina, A. M. Osadchuk & M. A. Osadchuk. (2019) Stroke prevention for non-valvular atrial fibrillation: how to make the right choice of directly acting oral anticoagulants?. Russian Journal of Cardiology:1, pages 94-102.
Crossref
Crossref
Jin-Kyu Park, Jun Kim, Yong Soo Baek, So-Ryoung Lee, You Mi Hwang, Tae-Hoon Kim, Dae In Lee, Ki Hong Lee, Jaemin Shim & Boyoung Joung. (2019) 2018 KHRS Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Korean Patients with Atrial Fibrillation: How to Initiate and Organize the Follow-up. The Korean Journal of Medicine 94:1, pages 17-39.
Crossref
Crossref
Paolo Verdecchia, Antonio D’Onofrio, Vincenzo Russo, Francesco Fedele, Francesco Adamo, Giulia Benedetti, Fabio Ferrante, Corrado Lodigiani, Francesco Paciullo, Adolfo Aita, Claudia Bartolini, Maria Gabriella Molini, Andrea Di Lenarda, Carmine Mazzone, Lorenza Scotti, Elena Paola Lanati & Arianna Iorio. (2019) Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study. Journal of Cardiovascular Medicine 20:2, pages 66-73.
Crossref
Crossref
Wilbert S. Aronow & Tatyana A. Shamliyan. (2019) Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation. American Journal of Therapeutics 26:6, pages e679-e703.
Crossref
Crossref
Ping G. Tepper, Jack Mardekian, Cristina Masseria, Hemant Phatak, Shital Kamble, Younos Abdulsattar, William Petkun & Gregory Y. H. Lip. (2018) Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban. PLOS ONE 13:11, pages e0205989.
Crossref
Crossref
Roberto Petidier Torregrossa, Pedro Abizanda Soler, Alicia Noguerón García, María Gonzalo Lázaro, José Gutiérrez Rodríguez, Pedro Gil Gregorio, F. Javier Martín-Sánchez, Pedro Ruíz-Artacho, Óscar Duems Noriega & Fernando Veiga Fernández. (2018) Anticoagulación en población anciana con fibrilación auricular no valvular. Artículo de revisión. Revista Española de Geriatría y Gerontología 53:6, pages 344-355.
Crossref
Crossref
Douglas Wan, Jeff S. Healey & Chris S. Simpson. (2018) The Guideline-Policy Gap in Direct-Acting Oral Anticoagulants Usage in Atrial Fibrillation: Evidence, Practice, and Public Policy Considerations. Canadian Journal of Cardiology 34:11, pages 1412-1425.
Crossref
Crossref
Stefania Angela Di Fusco, Fabiana Lucà, Manuela Benvenuto, Annamaria Iorio, Damiana Fiscella, Fabrizio D'Ascenzo, Andrea Madeo, Furio Colivicchi, Andrea Di Lenarda & Michele Massimo Gulizia. (2018) Major bleeding with old and novel oral anticoagulants: How to manage it. Focus on general measures. International Journal of Cardiology 268, pages 80-84.
Crossref
Crossref
Renato D. Lopes, Jan Steffel, Manuela Di Fusco, Allison Keshishian, Xuemei Luo, Xiaoyan Li, Cristina Masseria, Melissa Hamilton, Keith Friend, Kiran Gupta, Jack Mardekian, Xianying Pan, Onur Baser & W. Schuyler Jones. (2018) Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease. The American Journal of Medicine 131:9, pages 1075-1085.e4.
Crossref
Crossref
Matthias Zirk, Max Zinser, Johannes Buller, Viktor Bilinsky, Timo Dreiseidler, Joachim E. Zöller & Matthias Kreppel. (2018) Supportive topical tranexamic acid application for hemostasis in oral bleeding events – Retrospective cohort study of 542 patients. Journal of Cranio-Maxillofacial Surgery 46:6, pages 932-936.
Crossref
Crossref
Jan Steffel, Peter Verhamme, Tatjana S Potpara, Pierre Albaladejo, Matthias Antz, Lien Desteghe, Karl Georg Haeusler, Jonas Oldgren, Holger Reinecke, Vanessa Roldan-Schilling, Nigel Rowell, Peter Sinnaeve, Ronan Collins, A John Camm, Hein Heidbüchel, Gregory Y H Lip, Jeffrey Weitz, Laurent Fauchier, Deirdre Lane, Giuseppe Boriani, Andreas Goette, Roberto Keegan, Robert MacFadyen, Chern-En Chiang, Boyoung Joung & Wataru Shimizu. (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal 39:16, pages 1330-1393.
Crossref
Crossref
Ki Hong Lee, Boyoung Joung, So-Ryoung Lee, You Mi Hwang, Junbeom Park, Yong Soo Baek, Yae Min Park, Jin-Kyu Park, Hwan Cheol Park, Hyung Wook Park, Young Soo Lee & Kee Joon Choi. (2018) 2018 KHRS Expert Consensus Recommendation for Oral Anticoagulants Choice and Appropriate Doses: Specific Situation and High Risk Patients. The Korean Journal of Medicine 93:2, pages 110-132.
Crossref
Crossref
Michelangelo Sartori & Benilde Cosmi. (2018) Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy. Journal of Thrombosis and Thrombolysis 45:3, pages 345-352.
Crossref
Crossref
Satoshi Ogawa, Kazuo Minematsu, Takanori Ikeda, Takanari Kitazono, Jyoji Nakagawara, Susumu Miyamoto, Yuji Murakawa, Yohei Ohashi, Makiko Takeichi, Yutaka Okayama, Satoshi Yamanaka & Lyo Inuyama. (2018)
Design and baseline characteristics of the Xarelto Post‐Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (
XAPASS
)
. Journal of Arrhythmia 34:2, pages 167-175.
Crossref
Crossref
Davide Imberti & Giovanni Barillari. (2017) Real-Life Management of Venous Thromboembolism With Rivaroxaban: Results From EXperience VTE, an Italian Epidemiological Survey. Clinical and Applied Thrombosis/Hemostasis 24:2, pages 241-247.
Crossref
Crossref
Hsin-Yi Huang, Shin-Yi Lin, Shou-Hsia Cheng & Chi-Chuan Wang. (2018) Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study. Scientific Reports 8:1.
Crossref
Crossref
A John Camm, Keith A A Fox & Eric Peterson. (2018) Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention. EP Europace 20:1, pages 1-11.
Crossref
Crossref
Adolfo Romero Arana. (2018) Adherencia al tratamiento anticoagulante con apixabán y rivaroxabán en un entorno real. Enfermería Clínica 28:1, pages 63-64.
Crossref
Crossref
Adolfo Romero Arana. (2018) Adherence to anticoagulant treatment with apixaban and rivaroxaban in a real environment. Enfermería Clínica (English Edition) 28:1, pages 63-64.
Crossref
Crossref
Jeffrey S. Berger, Roger Seheult, François Laliberté, Concetta Crivera, Dominique Lejeune, Yongling Xiao, Jeff Schein, Patrick Lefebvre & Scott Kaatz. (2018) Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis 2:1, pages 58-68.
Crossref
Crossref
Géric Maura, Cécile Billionnet, François Alla, Joshua J. Gagne & Antoine Pariente. (2018) Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:1, pages 6-18.
Crossref
Crossref
Faye L. Norby, Lindsay G.S. Bengtson, Pamela L. Lutsey, Lin Y. Chen, Richard F. MacLehose, Alanna M. Chamberlain, Ian Rapson & Alvaro Alonso. (2017) Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation. BMC Cardiovascular Disorders 17:1.
Crossref
Crossref
Alberto Conti, Noemi Renzi, Daniele Molesti, Simone Bianchi, Irene Bogazzi, Giada Bongini, Giuseppe Pepe, Fabiana Frosini, Alessio Bertini & Massimo Santini. (2017) Short and long-term mortality of patients presenting with bleeding events to the Emergency Department. The American Journal of Emergency Medicine 35:12, pages 1867-1872.
Crossref
Crossref
Sven Pannach, Julia Goetze, Sandra Marten, Thomas Schreier, Luise Tittl & Jan Beyer-Westendorf. (2017) Management and outcome of gastrointestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs. Journal of Gastroenterology 52:12, pages 1211-1220.
Crossref
Crossref
Endalkachew Admassie, Leanne Chalmers & Luke R. Bereznicki. (2017) Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study. European Journal of Clinical Pharmacology 73:12, pages 1681-1689.
Crossref
Crossref
Marcelo Sanmartín-Fernández & Domingo Marzal-Martín. (2016) Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis 23:7, pages 711-724.
Crossref
Crossref
Faye L Norby & Alvaro Alonso. (2017) Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation. Journal of Comparative Effectiveness Research 6:6, pages 549-560.
Crossref
Crossref
Joshua D. BrownAnand R. ShewaleJeffery C. Talbert. (2017) Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data. Journal of Managed Care & Specialty Pharmacy 23:9, pages 958-967.
Crossref
Crossref
George NtaiosVasileios PapavasileiouKonstantinos MakaritsisKonstantinos VemmosPatrik MichelGregory Y.H. Lip. (2017) Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation. Stroke 48:9, pages 2494-2503.
Crossref
Crossref
Luca Monaco, Chiara Biagi, Valentino Conti, Mauro Melis, Monia Donati, Mauro Venegoni, Alberto Vaccheri & Domenico Motola. (2017) Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. British Journal of Clinical Pharmacology 83:7, pages 1532-1543.
Crossref
Crossref
Abdulaali R. Almutairi, Lili Zhou, Walid F. Gellad, Jeannie K. Lee, Marion K. Slack, Jennifer R. Martin & Wei-Hsuan Lo-Ciganic. (2017) Effectiveness and Safety of Non–vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. Clinical Therapeutics 39:7, pages 1456-1478.e36.
Crossref
Crossref
Alok A. Khorana, Jeffrey S. Berger, Philip S. Wells, Roger Seheult, Veronica Ashton, François Laliberté, Concetta Crivera, Dominique Lejeune, Jeff Schein, Peter Wildgoose, Patrick Lefebvre & Scott Kaatz. (2017) Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE. Clinical Therapeutics 39:7, pages 1396-1408.
Crossref
Crossref
Yasuo Terayama. (2017) Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients—Analysis of Pharmaceuticals and Medical Devices Agency Data. Journal of Stroke and Cerebrovascular Diseases 26:6, pages 1171-1181.
Crossref
Crossref
Maria Cristina Vedovati, Paolo Verdecchia, Michela Giustozzi, Gabriella Molini, Serenella Conti, Lucia Pierpaoli, Francesca Valecchi, Adolfo Aita, Giancarlo Agnelli & Cecilia Becattini. (2017) Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation. International Journal of Cardiology 236, pages 363-369.
Crossref
Crossref
Danilo Toni, Antonio Carolei, Valeria Caso, Domenico Consoli, Massimo Del Sette, Domenico Inzitari, Maurizio Melis, Giuseppe Micieli, Leandro Provinciali, Stefano Ricci, Paola Santalucia & Vito Toso. (2017) Use of rivaroxaban in patients with stroke. Neurological Sciences 38:5, pages 745-754.
Crossref
Crossref
Ying BaiHai DengAlena ShantsilaGregory Y.H. Lip. (2017) Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation. Stroke 48:4, pages 970-976.
Crossref
Crossref
V. Barrios & C. Escobar. (2017) De los ensayos clínicos a la práctica clínica. Evidencias con rivaroxaban en el tratamiento anticoagulante del paciente con fibrilación auricular no valvular. SEMERGEN - Medicina de Familia 43:3, pages 222-229.
Crossref
Crossref
Andreas Zirlik & Christoph Bode. (2016) Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis 43:3, pages 365-379.
Crossref
Crossref
Vincenzo Russo, Anna Rago, Riccardo Proietti, Federica Di Meo, Andrea Antonio Papa, Paolo Calabrò, Antonio D’Onofrio, Gerardo Nigro & Ahmed AlTurki. (2016) Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Therapeutic Advances in Drug Safety 8:2, pages 67-75.
Crossref
Crossref
Jan C. Purrucker & Thorsten Steiner. (2017) Management of acute stroke in patients on oral anticoagulants. Current Opinion in Neurology 30:1, pages 1-7.
Crossref
Crossref
Inmaculada Hernandez & Yuting Zhang. (2016) Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data. American Journal of Cardiovascular Drugs 17:1, pages 37-47.
Crossref
Crossref
Boyoung Joung. (2017) Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients. Korean Circulation Journal 47:6, pages 833.
Crossref
Crossref
Valeria Raparelli, Marco Proietti, Roberto Cangemi, Gregory Y. H. Lip, Deirdre A. Lane & Stefania Basili. (2017) Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Thrombosis and Haemostasis 117:02, pages 209-218.
Crossref
Crossref
Adam J. Singer, Adam Quinn, Neil Dasgupta & Henry C. ThodeJr.Jr.. (2017) Management and Outcomes of Bleeding Events in Patients in the Emergency Department Taking Warfarin or a Non–Vitamin K Antagonist Oral Anticoagulant. The Journal of Emergency Medicine 52:1, pages 1-7.e1.
Crossref
Crossref
Emanuel Raschi, Matteo Bianchin, Walter Ageno, Roberto De Ponti & Fabrizio De Ponti. (2016) Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies. Drug Safety 39:12, pages 1175-1187.
Crossref
Crossref
Joshua D. BrownAnand R. ShewaleJeffery C. Talbert. (2016) Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation. Journal of Managed Care & Specialty Pharmacy 22:11, pages 1319-1329.
Crossref
Crossref
Anders Gorst-Rasmussen, Gregory Y. H. Lip & Torben Bjerregaard Larsen. (2016) Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiology and Drug Safety 25:11, pages 1236-1244.
Crossref
Crossref
Geoffrey D Barnes & Brian Kurtz. (2016) Direct oral anticoagulants: unique properties and practical approaches to management. Heart 102:20, pages 1620-1626.
Crossref
Crossref
Alpesh Amin & Joel C. Marrs. (2016) Direct Oral Anticoagulants for the Management of Thromboembolic Disorders. Clinical and Applied Thrombosis/Hemostasis 22:7, pages 605-616.
Crossref
Crossref
Laurent Macle, John Cairns, Kori Leblanc, Teresa Tsang, Allan Skanes, Jafna L. Cox, Jeff S. Healey, Alan Bell, Louise Pilote, Jason G. Andrade, L. Brent Mitchell, Clare Atzema, David Gladstone, Mike Sharma, Subodh Verma, Stuart Connolly, Paul Dorian, Ratika Parkash, Mario Talajic, Stanley Nattel & Atul Verma. (2016) 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology 32:10, pages 1170-1185.
Crossref
Crossref
Kehinde O. Obamiro, Leanne Chalmers & Luke R. E. Bereznicki. (2016) A Summary of the Literature Evaluating Adherence and Persistence with Oral Anticoagulants in Atrial Fibrillation. American Journal of Cardiovascular Drugs 16:5, pages 349-363.
Crossref
Crossref
Gregory Y. H. Lip, Xianying Pan, Shital Kamble, Hugh Kawabata, Jack Mardekian, Cristina Masseria, Amanda Bruno & Hemant Phatak. (2016) Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States. International Journal of Clinical Practice 70:9, pages 752-763.
Crossref
Crossref
Jan Beyer-Westendorf, Birgit Ehlken & Thomas Evers. (2016) Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace 18:8, pages 1150-1157.
Crossref
Crossref
John K. Abdou, Vivian Auyeung, Jignesh P. Patel & Roopen Arya. (2016) Adherence to long-term anticoagulation treatment, what is known and what the future might hold. British Journal of Haematology 174:1, pages 30-42.
Crossref
Crossref
Ying He, Ian C. K. Wong, Xue Li, Shweta Anand, Wai K. Leung, Chung Wah Siu & Esther W. Chan. (2016) The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies. British Journal of Clinical Pharmacology 82:1, pages 285-300.
Crossref
Crossref
L. Deville, M. Konan, A. Hij, L. Goldwirt, O. Peyrony, F. Fieux, P. Faure, I. Madelaine, S. Villiers, D. Farge-Bancel & C. Frère. (2016) Major bleeding complications in patients treated with direct oral anticoagulants: One-year observational study in a Paris Hospital. Current Research in Translational Medicine 64:3, pages 129-133.
Crossref
Crossref
Craig I. Coleman, Muralikrishna Tangirala & Thomas Evers. (2016) Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States. PLOS ONE 11:6, pages e0157769.
Crossref
Crossref
Jason G. Andrade, Andrew D. Krahn, Allan C. Skanes, Daniel Purdham, Antonio Ciaccia & Sean Connors. (2016) Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention. Canadian Journal of Cardiology 32:6, pages 747-753.
Crossref
Crossref
Marek Jauß, Sibylle Kaiser & Christian Tanislav. (2016) Neue Einsichten durch Real-World-Daten zu oralen Non-Vitamin-K-Antikoagulanzien. InFo Neurologie & Psychiatrie 18:6, pages 46-60.
Crossref
Crossref
Guowei Li, Anne Holbrook, Yanling Jin, Yonghong Zhang, Mitchell A. H. Levine, Lawrence Mbuagbaw, Daniel M. Witt, Mark Crowther, Stuart Connolly, Chatree Chai-Adisaksopha, Zhongxiao Wan, Ji Cheng & Lehana Thabane. (2016) Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials. European Journal of Epidemiology 31:6, pages 541-561.
Crossref
Crossref
Marco Proietti & Gregory Y.H. Lip. (2016) Atrial Fibrillation and Stroke. Cardiology Clinics 34:2, pages 317-328.
Crossref
Crossref
Sotiris Antoniou & Walid Amara. (2016) Once-daily rivaroxaban for long-term stroke prevention in patients with atrial fibrillation. European Heart Journal Supplements 18:suppl D, pages D7-D15.
Crossref
Crossref
A. John Camm, Pierre Amarenco, Sylvia Haas, Susanne Hess, Paulus Kirchhof, Silvia Kuhls, Martin van Eickels & Alexander G.G. Turpie. (2016) XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. European Heart Journal 37:14, pages 1145-1153.
Crossref
Crossref
Walid Amara & Sotiris Antoniou. (2016) Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal Supplements 18:suppl D, pages D1-D6.
Crossref
Crossref
Alan D. Bell, Peter Gross, Michael Heffernan, Yan Deschaintre, Jean-Francois Roux, Daniel M. Purdham & Ashfaq Shuaib. (2016) Appropriate Use of Antithrombotic Medication in Canadian Patients With Nonvalvular Atrial Fibrillation. The American Journal of Cardiology 117:7, pages 1107-1111.
Crossref
Crossref
Tomas Forslund, Björn Wettermark & Paul Hjemdahl. (2015) Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. European Journal of Clinical Pharmacology 72:3, pages 329-338.
Crossref
Crossref
Hans-Christoph Diener, James Aisenberg, Jack Ansell, Dan Atar, Günter Breithardt, John Eikelboom, Michael D. Ezekowitz, Christopher B. Granger, Jonathan L. Halperin, Stefan H. Hohnloser, Elaine M. Hylek, Paulus Kirchhof, Deirdre A. Lane, Freek W.A. Verheugt, Roland Veltkamp & Gregory Y.H. Lip. (2016) Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. European Heart Journal, pages ehw069.
Crossref
Crossref
Edward Koifman, Michael J. Lipinski, Ricardo O. Escarcega, Romain Didier, Sarkis Kiramijyan, Rebecca Torguson & Ron Waksman. (2016) Comparison of Watchman device with new oral anti-coagulants in patients with atrial fibrillation: A network meta-analysis. International Journal of Cardiology 205, pages 17-22.
Crossref
Crossref
Judith Hecker, Sandra Marten, Loretta Keller, Sindy Helmert, Franziska Michalski, Sebastian Werth, Kurtulus Sahin, Luise Tittl & Jan Beyer-Westendorf. (2017) Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Thrombosis and Haemostasis 115:05, pages 939-949.
Crossref
Crossref
Carlos Martinez, Anja Katholing, Christopher Wallenhorst & Saul Benedict Freedman. (2017) Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. Thrombosis and Haemostasis 115:01, pages 31-39.
Crossref
Crossref
Juan Antonio Millón Caño, Noelia Vilalta Setó, José Mateo Arranz & Juan Carlos Souto Andrés. (2016) Importancia del empleo adecuado de los anticoagulantes orales directos. Medicina Clínica 146:1, pages 41-42.
Crossref
Crossref
Juan Antonio Millón Caño, Noelia Vilalta Setó, José Mateo Arranz & Juan Carlos Souto Andrés. (2016) Importance of appropriate clinical management of direct oral anticoagulants. Medicina Clínica (English Edition) 146:1, pages 41-42.
Crossref
Crossref
Craig I. Coleman, Matthias Antz, Birgit Ehlken & Thomas Evers. (2016) REal-LIfe Evidence of stroke prevention in patients with atrial Fibrillation — The RELIEF study. International Journal of Cardiology 203, pages 882-884.
Crossref
Crossref
K. Hogg, B. Bahl, M. Latrous, S. Scaffidi Argentina, J. Thompson, A. A. Chatha, L. Castellucci & I. G. Stiell. (2015) Time trends in intracranial bleeding associated with direct oral anticoagulants: a 5-year cohort study. CMAJ Open 3:4, pages E432-E437.
Crossref
Crossref
María Monteagudo, Eva Fernández-Díaz, Jorge García-García, Óscar Ayo-Martín, Francisco Hernández-Fernández & Tomás Segura. (2015) Efficacy, safety and tolerability of rivaroxaban for the secondary prevention of stroke in patients with atrial fibrillation in clinical practice. Future Neurology 10:6, pages 529-536.
Crossref
Crossref
Liang Lin, Wee Shiong Lim, Hui Jun Zhou, Ai Leng Khoo, Keng Teng Tan, Aik Phon Chew, David Foo, Jing Jih Chin & Boon Peng Lim. (2015) Clinical and Safety Outcomes of Oral Antithrombotics for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Network Meta-analysis. Journal of the American Medical Directors Association 16:12, pages 1103.e1-1103.e19.
Crossref
Crossref
Jamshed Dalal, Abhay Bhave, Abraham Oomman, Amit Vora, Anil Saxena, Dhiman Kahali, Fali Poncha, D.S. Gambhir, Jaydip Ray Chaudhuri, Nakul Sinha, Saumitra Ray, S.S. Iyengar, Suvro Banerjee & Upendra Kaul. (2015) The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants. Indian Heart Journal 67, pages S13-S34.
Crossref
Crossref
Susan Hanemaaijer, Fong Sodihardjo, Annemieke Horikx, Michel Wensing, Peter A. G. M. De Smet, Marcel L. Bouvy & Martina Teichert. (2015) Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands. International Journal of Clinical Pharmacy 37:6, pages 1128-1135.
Crossref
Crossref
Vivencio Barrios & José Luis Górriz. (2015) Atrial fibrillation and chronic kidney disease: focus on rivaroxaban. Journal of Comparative Effectiveness Research 4:6, pages 651-664.
Crossref
Crossref
Géric MauraPierre-Olivier BlotièreKim BouillonCécile BillionnetPhilippe RicordeauFrançois AllaMahmoud Zureik. (2015) Comparison of the Short-Term Risk of Bleeding and Arterial Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Newly Treated With Dabigatran or Rivaroxaban Versus Vitamin K Antagonists. Circulation 132:13, pages 1252-1260.
Crossref
Crossref
Jiang Xie, Yong-Xiang Wei, Shuang Liu, Wei Zhang, Xiang-Feng Zhang & Jie Li. (2015) Obstructive Sleep Apnea Hypopnea Syndrome as a Reason for Active Management of Pulmonary Embolism. Chinese Medical Journal 128:16, pages 2147-2153.
Crossref
Crossref
Miguel Hernández Olmedo & Carmen Suárez Fernández. (2015) Avances en el tratamiento anticoagulante de la fibrilación auricular. Medicina Clínica 145:3, pages 124-130.
Crossref
Crossref
Miguel Hernández Olmedo & Carmen Suárez Fernández. (2015) Progress of anticoagulation therapy in atrial fibrillation. Medicina Clínica (English Edition) 145:3, pages 124-130.
Crossref
Crossref
Manuj SharmaVictoria R. CorneliusJignesh P. PatelJ. Graham DaviesMariam Molokhia. (2015) Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism. Circulation 132:3, pages 194-204.
Crossref
Crossref
Mikhail S. Dzeshka & Gregory Y.H. Lip. (2015) Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?. Trends in Cardiovascular Medicine 25:4, pages 315-336.
Crossref
Crossref
J. Beyer-Westendorf, K. Forster, F. Ebertz, V. Gelbricht, T. Schreier, M. Gobelt, F. Michalski, H. Endig, K. Sahin, L. Tittl & N. Weiss. (2015) Drug persistence with rivaroxaban therapy in atrial fibrillation patients--results from the Dresden non-interventional oral anticoagulation registry. Europace 17:4, pages 530-538.
Crossref
Crossref
B. Vrijens & H. Heidbuchel. (2015) Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace 17:4, pages 514-523.
Crossref
Crossref
J. Bosch & J. W. Eikelboom. (2017) Management of bleeding with oral anticoagulants in patients with atrial fibrillation. Hämostaseologie 35:04, pages 351-357.
Crossref
Crossref
Hiroo Terashi, Tomoko Saitou, Makiko Kobayashi, Youhei Ishimura, Yurie Suzuki, Aya Inoue, Takeshi Taguchi, Haruhisa Katou & Hitoshi Aizawa. (2015) Clinical trial and the real world. Cerebral Blood Flow and Metabolism (Japanese journal of cerebral blood flow and metabolism) 26:2, pages 63-66.
Crossref
Crossref
Naoki Saji, Kazumi Kimura, Junya Aoki, Junichi Uemura & Yuki Sakamoto. (2015) Intracranial Hemorrhage Caused by Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) – Multicenter Retrospective Cohort Study in Japan –. Circulation Journal 79:5, pages 1018-1023.
Crossref
Crossref